Compare JHS & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JHS | ACOG |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5M | 129.4M |
| IPO Year | 1994 | N/A |
| Metric | JHS | ACOG |
|---|---|---|
| Price | $11.01 | $5.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 17.6K | ★ 57.2K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.62 | $3.75 |
| 52 Week High | $12.09 | $10.88 |
| Indicator | JHS | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 51.49 |
| Support Level | $11.01 | $5.16 |
| Resistance Level | $11.40 | $6.67 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 4.62 | 51.00 |
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.